The Next Step from High-Flux Dialysis: Application of Sorbent Technology
Citations Over TimeTop 18% of 2002 papers
Abstract
The current foci of renal replacement therapy with dialysis are middle molecular weight toxins, consisting of small proteins, polypeptides and products of glycosylation and lipoxygenation. Conventional high-flux dialysis is not efficient at removing these molecules, explaining the increased interest in using sorbents to supplement dialysis techniques. Prototype biocompatible sorbents have been developed and investigated for middle molecule removal; these have been shown, in man, to remove beta(2)-microglobulin, angiogenin, leptin, cytokines and other molecules, without reducing platelets and leukocytes. Extensive clinical studies are underway to demonstrate the clinical utility and safety of adding routinely a sorbent hemoperfusion device to hemodialysis.
Related Papers
- → Effect of the Combination of Hemodialysis and Hemoperfusion on Clearing Advanced Glycation End Products: A Prospective, Randomized, Two-Stage Crossover Trial in Patients Under Maintenance Hemodialysis(2015)23 cited
- → Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis(1992)18 cited
- Outcomes of blood purification on clearance of serum advanced glycation end products and beta 2-microglobulin(2010)
- → Comparison of effect of different hemodialysis methods on clearance of serum cystantin c in uremic patients(2012)
- → Effect of high throughput hemodialysis and hemoperfusion on clearance of beta 2-microglobulin in nephritis(2020)